Winter and spring are the peak seasons for influenza A and B. At present, COVID-19 is still developing. The infections of three viruses including influenza A, B and COVID-19 are relatively similar and all can have respiratory symptoms such as fever and cough. This is also a challenge in the prevention and control of the COVID-19 pandemic. How to quickly realize the differential diagnosis of respiratory pathogens plays an important role in the prevention and control of epidemic situation.

On November 5, the National Health Commission released the latest version of the 2020 influenza diagnosis and treatment plan, which added the differential diagnosis of influenza and novel coronavirus, mentioning antigens, nucleic acids, virus culture and serological testing methods. Hybribio’s R&D team conducted specific tests on a variety of respiratory pathogens, and continuously optimized the reaction system to develop “COVID-19, Flu A and B Multiplex Real-time PCR Kit” which is used to identify and detect the nucleic acid of the novel coronavirus, influenza A and B virus in the throat swab samples of suspected infected people. The testing kit has recently obtained the EU CE certification and complied with EU’s requirements about medical devices. It has met the conditions to enter the EU market.

“COVID-19, Flu A and B Multiplex Real-time PCR Kit” can detect three kinds of viruses at once. It has the characteristics of fast and efficient, high sensitivity, strong specificity, etc. Fully automated extraction and amplification are convenient and safe to operate, and results can be obtained within 1.5 hours. It has significant advantages in sensitivity, specificity and accuracy, and is used for clinical practices and rapid triage of testing populations, precise prevention and control of the COVID-19 epidemic, as well as providing practical diagnostic evidence and results for the clinical practices.

At present, Hybribio is able to provide many kinds of anti-COVID products for the world, including “COVID-19 Real-Time PCR Kit, COVID-19, Flu A and B Multiplex Real-time PCR Kit”, automatic nucleic acid extraction apparatus 4801A, automatic nucleic acid extractor 9600A, nuclear acid extraction and purification reagent, sample preservation solution and other products, creating a rapid detection solution for COVID-19 which can meet a variety of application scenarios and clinical needs.

“COVID-19, Flu A and B Multiplex Real-time PCR Kit” has been certified by CE. Hybribio will help to prevent and control the epidemic globally with a more comprehensive product plan. Next, the “COVID-19, Flu A and B Multiplex Real-time PCR Kit” will successively apply for entry into the export whitelist of the Ministry of Commerce and obtain export sales certificates and other passes to contribute to global epidemic prevention and control as a national brand.

We sincerely invite global partners:

Email: isw@hybribio.cn

Tel: 0768-2852923-6193